Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biogazelle Serves as Reference Laboratory for Bio-Rad's ddPCR System

Published: Monday, September 30, 2013
Last Updated: Monday, September 30, 2013
Bookmark and Share
Biogazelle’s and Bio-Rad’s long-term partnership extends.

Biogazelle has announced that it is serving a reference laboratory for Bio-Rad’s QX200™ Digital Droplet PCR™ system (ddPCR) in Europe. This extends Biogazelle’s and Bio-Rad’s long-term partnership for PCR-based solutions.

As a reference laboratory, Biogazelle uses ddPCR in its R&D programs and shares its ddPCR user experience with the PCR community.

In addition, Biogazelle is acting as a ddPCR service provider for third parties who are interested in outsourcing a study. In addition, the Biogazelle laboratory also serves as a live research environment for prospective QX200 system customers.

Professor Jo Vandesompele, co-founder of Biogazelle, welcomes the agreement: "We are a young and dynamic company, eager to learn from and to teach the PCR research community. Being a reference center for ddPCR is completely in line with our mission to address unmet needs through excellence in science and technology."

Digital PCR is a nucleic acid quantification method with unprecedented resolution and relative sensitivity. It can determine how many nucleic acid target molecules are present in a particular sample by counting how many miniaturized reactions are positive if the template is partitioned into 1000’s of parallel reactions.

The QX200 system uses droplets as partitions to perform ddPCR. It is a flexible and high throughput instrument with an optimal number of partitions per sample. Both probe and dye based assays can be used.

Biogazelle is at the forefront of digital PCR-based research, as it was one of the first European laboratories that had access to the technology in 2012. The co-founders are also co-author on the digital MIQE guidelines (Huggett et al., Clinical Chemistry, 2013).

Biogazelle is working on various ddPCR projects, including (i) gene copy number quantification to determine the stability of transgenic cells or organisms, (ii) splice variant quantification, (iii) quantification of pathogenic organisms, and (iv) rare event detection for cancer diagnostics and monitoring of patient response to treatment.

By sharing its expertise in assay development, experiment design and nucleic acid quantification, Biogazelle aims to serve the digital PCR community. In addition, Biogazelle will use its experience to provide digital PCR services for academic and industrial customers.

Dr. Jan Hellemans, co-founder of Biogazelle, acknowledges the great potential digital PCR holds for clinical diagnostics. "Data interpretation is quite straightforward and results can easily be shared and interpreted among different users because absolute concentrations are determined. Moreover, its inherently high precision, accuracy and relative sensitivity are relevant features for laboratory tests that are used in the clinic. Biogazelle is proud to accelerate ddPCR discoveries, bringing ddPCR closer to the clinic."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Biogazelle and Isis Evaluate Long Non-coding RNAs
Identify and validate novel targets for anti-cancer drugs.
Saturday, October 17, 2015
Biogazelle Receives €1.1M IWT Funding
Funding to develop lncRNA targeting cancer therapies.
Wednesday, August 12, 2015
Biogazelle has Established a Quality Management System
Company is ISO 17025 accredited for gene expression services.
Tuesday, February 03, 2015
Biogazelle Attracts New Investors
UGent spin-off Biogazelle attracts new investors QBIC Arkiv Fund, Foundation Majoie and SOFI to finance growth.
Tuesday, October 07, 2014
VIB Inks qBase+ Group Licensing Agreement with Biogazelle
VIB to accelerate its qPCR analyses by using qbase+ as the software.
Monday, May 20, 2013
Biogazelle Appoints Kris Vanhercke as Chief Operating Officer
New appointment strengthens business development and marketing expertise of Biogazelle.
Monday, September 24, 2012
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!